B
Clinical-stage biotech developing BB-031, a reversible RNA aptamer thrombolytic for acute ischemic stroke.
At a glance
- HQ: Cary
- Sector: Biotech
- Stage: Series C
The rest of this record is behind a free account.
Founders, funding history, investor connections, and recent signals load on this page as soon as you sign in. Accounts open immediately, and I read every signup.